This was the finding of a comprehensive analysis of clinical trials covering more than 95,000 patients reported in The Lancet Diabetes and Endocrinology. The study was also presented at the 64th Annual Scientific Session of the American College of Cardiology in San Diego, CA, earlier this week.
Heart failure â€“ where the heart does not pump enough blood around the body at the right pressure â€“ is a common condition in patients with type 2 diabetes.
Heart failure has a major impact on the quality of life of patients and is a major driver of health care costs in the US.
The Centers for Disease Control and Prevention (CDC) estimate heart failure costs the nation $32 billion each year. This figure includes the cost of health care services, medications and missed days of work.
Fourteen trials involving a total of 95,502 participants matched their criteria. They pooled and analyzed the data to calculate the relative risks of heart failure posed by each of the type 2 diabetes medications or treatments.
A heart failure event occurred in 4% of patients during the individual trials they participated in, while 9.8% suffered a major cardiovascular event, such as heart attack or stroke.
14% increased risk of heart failure in patients on sugar-lowering drugs to manage diabetes
Lead investigator Dr. Jacob Udell, of the Peter Munk Cardiac Centre at the University Health Network (UHN) and the Womenâ€™s College Hospital (WCH), both in Toronto, Canada, says they found:
- Breathlessness, tiredness and swollen ankles are the main symptoms of heart failure
- While it is a serious condition, it does not mean the heart has stopped beating
- About 5.1 million people in the US have heart failure.
He explains that the â€œincreased risk was directly associated with the type of diabetes therapy that was chosen, with some drugs more likely to cause heart failure than others, compared with placebo or standard care.â€
In the following video, Dr. Udell summarizes the findings and implications of their study for patients, doctors and researchers:
Dr. Barry Rubin, medical director of the Peter Munk Cardiac Centre at UHN, says: